Fatty liver disease (MASLD/MASH) trials in Hong Kong
14 trials · From ClinicalTrials.gov, checked 10 Nov 2026. Ask the study team whether a trial fits you.
Phase 3RecruitingTrial-stage medicine
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Where
- Hong Kong
- Age
- 18 years and over
- People
- 1,800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632444EU 2024-513739-25-00Registry updated 2026-10-28
Phase 3RecruitingTrial-stage medicine
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Where
- Hong Kong
- Age
- 18 years and over
- People
- 1,590 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632457EU 2024-513741-36-00Registry updated 2026-10-28
Phase 3RecruitingTrial-stage medicine
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- Where
- Hong Kong, Shatin
- Age
- 18 years to 80 years
- People
- 1,350 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06318169EU 2023-509912-27-00Registry updated 2026-10-23
Phase 3RecruitingTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- Where
- Hong Kong, Shatin
- Age
- 18 years to 75 years
- People
- 1,800 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06419374EU 2023-510395-31-00Registry updated 2026-10-23
Phase 3RecruitingTrial-stage medicine
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Where
- Hksar, Shatin, Tuenmen
- Age
- 18 years and over
- People
- 4,500 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07165028EU 2025-522674-36-00Registry updated 2026-10-08
Phase 3RecruitingTrial-stage medicine
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- Where
- Pokfulam
- Age
- 18 years to 75 years
- People
- 1,250 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07221188EU 2025-523674-16-00Registry updated 2026-09-17
No phaseRecruitingResearch participation
Duodenal pulsENDO as an Early Treatment for Type 2 DM
- Where
- Shatin
- Age
- 18 years to 60 years
- People
- 40
- Run by
- Chinese University of Hong Kong
See details and how to joinNCT07376486Registry updated 2026-09-15
No phaseRecruitingResearch participation
Duodenal pulsENDO for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease
- Where
- Shatin
- Age
- 18 years to 70 years
- People
- 40
- Run by
- Chinese University of Hong Kong
See details and how to joinNCT07390422Registry updated 2026-09-15
No phaseRecruitingResearch participation
Longitudinal Observational Study Of Chinese With NAFLD/NASH
- Where
- Hong Kong
- Age
- 18 years and over
- People
- 20,000
- Run by
- Humanity and Health Research Centre
See details and how to joinNCT03151473Registry updated 2026-07-29
Phase 3RecruitingTrial-stage medicine
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- Where
- Pokfulam
- Age
- 18 years to 75 years
- People
- 1,200 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07221227Registry updated 2026-07-27
No phaseRecruitingResearch participation
Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With Obesity
- Where
- Hong Kong
- Age
- 18 years and over
- People
- 200
- Run by
- Chinese University of Hong Kong
See details and how to joinNCT07662356Registry updated 2026-06-23
No phaseRecruitingResearch participation
Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention
- Where
- Hong Kong
- Age
- 18 years to 65 years
- People
- 80
- Run by
- Chinese University of Hong Kong
See details and how to joinNCT03875625Registry updated 2025-02-13
No phaseRecruitingResearch participation
Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter
- Where
- Hong Kong
- Age
- 18 years to 65 years
- People
- 150
- Run by
- Chinese University of Hong Kong
See details and how to joinNCT06203548Registry updated 2024-08-09
No phaseRecruitingResearch participation
Vigorous- Versus Moderate-intensity Exercise to Reduce Liver Fat in Adults With Obesity and NAFLD
- Where
- Hong Kong
- Age
- 18 years to 69 years
- People
- 330
- Run by
- The University of Hong Kong
See details and how to joinNCT06124456Registry updated 2024-07-09
All Fatty liver disease (MASLD/MASH) trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.